Nimbus Salacia Inc. has disclosed new serine/threonine-protein kinase SIK2 (QIK) inhibitors potentially useful for the treatment of autoimmune disease, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.
Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that regulates transcriptional programs in myeloid cells by phosphorylating transcriptional coregulators. In macrophages, SIK2 promotes the expression of proinflammatory cytokines and contributes to the balance between inflammatory and regulatory responses. Researchers from Nimbus Therapeutics LLC presented the preclinical efficacy of NTX-147, a SIK2 selective inhibitor, in ex vivo models of ulcerative colitis (UC).
Nimbus Salacia Inc. has disclosed serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.
Researchers from Sitryx Therapeutics Ltd. and affiliated organizations presented data from a study that aimed to assess the potential of selective salt-inducible kinase 2 (SIK2) inhibition as a therapeutic strategy for the treatment of ulcerative colitis.
Shanghai Meiyue Biotech Development Co. Ltd. has identified serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of fibrosis, cancer, autoimmune diseases, transplant rejection, cardiovascular, dermatological, endocrine, and inflammatory disorders, among others.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 (QSK) inhibitors reported to be useful for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Shanghai Meiyue Biotech Development Co. Ltd. has disclosed serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of metabolic, autoimmune diseases, cardiovascular, dermatological, endocrine disorders, transplant rejection, fibrosis and inflammatory disorders.
